Autonomix Medical, Inc. · NASDAQ:AMIX
Autonomix Medical — Investor Presentation (April 2025)
18 slides from Autonomix Medical's investor presentation, Apr 30, 2025
Slide 1: Autonomix Investor Presentation April 2025
Nasdaq: AMIX AUTONOMIX Sense, Treat and Verify. Illuminating the Nervous System with Transvascular Precision-Guided Technology Investor Presentation Aprit 2025
Slide 2: Disclaimer
Disclaimer Al statements contained her in other than statements of historical fact, including statements regarding our future results of operations and ‘may “wit ? pate, 1 texpect We have based these forward-looking statoments largoly on our ‘nd tinanciat needs. are only predictions and i inties, an
Slide 3: Unleashing the Power of Autonomix Treatments
Unleashing the Power of AUTONOMIX Treatments y technology to treat neurological diseases CPC uey |) Extensive IP Portfolio with 120+ Patents Issued and Pending BPC S22" Senstiy to Detoct and Dierentiae Neural Signals Enabling Real-Time, High a Resolution Signal Capture Through Our Proprietary Microc
Slide 4: Current Technologies Cannot Precisely Target and Treat Overactive Nerves
Current Technologies Cannot Precisely Target and Treat Overactive Nerves Current cardiac sensing technologies cannot detect low amplitude neuronal signals Neuronal RF ablation procedures, while effective, are currently performed blind Clearer visibility and a better understanding of the nervous syst
Slide 5: Illuminating the Nervous System Technology
AUTONOMIX Nluminating the Nerv Technology > PP autonomix
Slide 6: Enabling: Sense, Treat and Verify
Enabling: Sense, Treat and Verify Sense (Identify) Treat (Ablate) 3) Verify (Confirm) Overactive Nerves Target Nerves Treatment SE ~ a Activity to Identity Target Delivers Thermal Energyto Kill Feedback Ensures Treatment Overactive Nerves faresthetes Effectiveness Precision Mapping of Neural ZB avro
Slide 7: Unleashing the Power of Precision-Guided, Nerve-Targeted Treatments
Unleashing the Power of Precision-Guided, Nerve-Targeted Treatments ised Technology to Detect Relevant als and Ablate Nerves in One Simple Procedure < 5yV AS|C-Powered! Platform High Sensitivity to Detect and Proprietary Sensory Unlimited Application Differentiate Neural Microchip q oO Wide Signal S
Slide 8: Processing Power Brought Directly to the Nerves
Processing Power Brought Directly to the Nerves Ez Signal travels 6 feet tobe processed = ‘Stronger cardiac electrical activity is capable of traveling distance without loss of signal and resolution. CURRENT es oF tothe sensor ty. ‘We took the equivalent of bulky <5 UV eginnenndraietd domaine PV Ste
Slide 9: First-in-Human Proof-of-Concept Trial in Pancreatic Cancer Pain
First-in-Human Proof-of- Concept Trialin Associated With Initial Phase Achieved Key Learnings and Met All Study Objectives Demonstrated Statistically Number of Subjects: 20' Clinical Sites: 1 Objective: Varsvascular ablation of tevant nerves to treat intractable pain A Major Unmet Need Negative Impa
Slide 10: Positive Data on Treatment of Pancreatic Cancer Pain
on Treatment of Pancreatic Cancer Pain Pain Reduction Remained Consistently Positive at 7-Days and 4-6 Weeks Post-Procedure No Device or Procedure-Related Serious Adverse Events! 100% of patients (n=16) with femoral access responded to treatme! Pain relief occurred as early as 24 hours post-procedur
Slide 11: Reduction in Pain With Improvement in Quality of Life
in Pain With Improvement in Quality of Life 100% of Responders Required Zero Opioid Use at 7 Days 73% of Responders Remained Opioid Free at 4-6 Weeks, Even with Disease Progression PoC 1: Reducing Severe Pain in Pancreatic Cancer 4-6 Week Data? pulation (n+): Responding Population (9) VAS Pain Opioi
Slide 12: Demonstrated Clinically Meaningful Pain Reduction at 7-Day & 4-6 Week Follow-Up
Demonstrated Clinically Meaningful Pain Reduction at 7-Day & 4-6 Week Follow-Up PANCREATIC CANCER PAIN PoC 1 STUDY: TIME Severe Pain Moderate ‘Sereening Post-Procedure 7 Days Follow-Up 16 (#24 Hours) (+/- 48 Hours) ne16 @ svronomix
Slide 13: Key Trial Highlights
Key Trial Highlights Follow-On Expansion Protocol of Proof-of- Evaluating Additional Visceral Concept Trial Cancers that Signal Ps Through the Celiac Plexus Pain Management in Additional Visceral Cancers as Well as Earlier Stage Pancreatic Cancer Fanon intctontional Cancer Pain Management in Viscera
Slide 14: Path to Potential FDA Clearance
Path to Potential FDA Clearance PoC 1 and IDE Clinical FDA De Novo PoC 2 Studies > | Trials in US | > | Submission > FDA Clearance in 2027 | Revenue Generation Model e Uo Capital Expenditure Catheter Disposables Annual Software License Grvron OMX
Slide 15: Proof-of-Concept in Lead Indication Opens >$100 Billion Market Opportunity
Proof-of-Concept in Lead Indication Opens >$100 Billion Total Market Opportunity Potential Future Targets Market Opportunities I ——_[s788} Initial Target L Gorvronomx 2 : : 1
Slide 16: Proven Team With Multiple Successful Exits
Proven Team With Multiple Successful Exits Brad Hauser Jennifer Cook Dr. Robert Schwartz Trent Smith Landy Toth @ LifeLens Allergan LB mUTONOMIX
Slide 17: Investment Summary
AUTONOMIX Investment Summary Unleashing the Power of Nerve-Targeted Treatments Transforming the diagnosis and Significant pain reduction Proven team with multiple treatment of pain and diseases of demonstrated in PoC 1 successful exits LIEENENES EU) Initiating Expansion Phase (PoC 2) in Additional V
Slide 18: Autonomix Contact
(7 AUTONOMIX ‘Company Investor / Media Relations eure) Shope! ees acne autonomix.com
Autonomix Medical — Investor Presentation (April 2025) on 6ix